Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
IPO Year:
Exchange: NASDAQ
Website: simulations-plus.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/30/2025 | $16.00 | Hold | TD Cowen |
| 7/15/2025 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 11/15/2024 | $39.00 | Overweight | Stephens |
| 7/29/2024 | $47.00 | Overweight | KeyBanc Capital Markets |
| 7/16/2024 | Mkt Perform | JMP Securities | |
| 6/28/2024 | Outperform | William Blair | |
| 5/9/2023 | $55.00 | Buy | BTIG Research |
| 10/26/2021 | $65.00 → $53.00 | Hold → Buy | Craig Hallum |
| 7/13/2021 | $95.00 → $54.00 | Outperform | Raymond James |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
TD Cowen initiated coverage of Simulations Plus with a rating of Hold and set a new price target of $16.00
KeyBanc Capital Markets downgraded Simulations Plus from Overweight to Sector Weight
Stephens initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $39.00
KeyBanc Capital Markets initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $47.00
JMP Securities initiated coverage of Simulations Plus with a rating of Mkt Perform
William Blair initiated coverage of Simulations Plus with a rating of Outperform
BTIG Research initiated coverage of Simulations Plus with a rating of Buy and set a new price target of $55.00
Craig Hallum upgraded Simulations Plus from Hold to Buy and set a new price target of $53.00 from $65.00 previously
Raymond James reiterated coverage of Simulations Plus with a rating of Outperform and set a new price target of $54.00 from $95.00 previously
Fastest customizable press release news feed in the world
Validated engines and AI-orchestrated ecosystem align with the emerging regulatory framework Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration's draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidance encourages reduced reliance on animal studies and elevates mechanistic understanding, pharmacokinetics, and integrated weight-of-evidence (WoE) assessments for nonclinical decision-making. "The FDA's draft guidance signals a clear regulatory mandate towa
Reaffirms fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10 Investor Day on January 21, 2026, to present new product vision and AI solutions Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025. Fourth Quarter 2025 Financial Highlights (as compared to fourth quarter 2024) Total revenue decreased 6% to $17.5 million Software revenue decreased 9% to $9.0 million, representi
Provides preliminary fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10 Fourth quarter and fiscal year 2025 results to be reported December 1, 2025 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary results for its fiscal year 2025 and issued preliminary guidance and management outlook for fiscal year 2026 as follows: Fiscal 2025 Preliminary Fiscal 2026 Guidance Revenue $
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the following investor events in September: 2025 Wells Fargo Healthcare Conference Format: Fireside chat and one-on-one meetings When: Wednesday and Thursday, September 3-4, 2025 Location: Boston, Massachusetts Webcast Link: Wednesday, September 3, 2025 at 12:45 PM ET here Morgan Stanley 23rd Annual Global Healthcare Conference Format: Fireside chat and one-on-one meetings
Researchers found 70% of compounds designed in ADMET Predictor demonstrated significant activity during in vitro testing Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that experimental results of its artificial intelligence-driven drug design (AIDD) collaboration with the Institute of Medical Biology of the Polish Academy of Sciences (IMB PAS) have been published in the American Chemical Society (ACS) Medical Chemistry Letters. Simulations Plus and IMB PAS launched their collaboration in 2023 to
Investment to accelerate innovations in biopharma development through Corporate Development Initiative Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor. Founded in 2017, Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceutical companies through digitalization in the clinical development phase. Its solution significantly accelerates the typical clinical trial lif
Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its third quarter fiscal 2025, ended May 31, 2025. Third Quarter 2025 Financial Highlights (as compared to third quarter 2024) Total revenue increased 10% to $20.4 million Software revenue increased 6% to $12.6 million, representing 62% of total revenue Services revenue increased 17% to $7.7 millio
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the Citizens Medical Devices and Healthcare Services Forum taking place in Boston, Massachusetts. Mr. O'Connor will host one-on-one meetings with institutional investors on Tuesday, June 17, 2025. For more information about the events or questions about registration, interested parties should reach out to their contacts at Citizens. About Simulations Plus, Inc. With more
Updates fiscal 2025 revenue guidance range Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue guidance. The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million Full year fiscal 2025 revenue is expected to range between $76 millio
8-K - Simulations Plus, Inc. (0001023459) (Filer)
10-K - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
SCHEDULE 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
10-Q - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
8-K/A - Simulations Plus, Inc. (0001023459) (Filer)
This live feed shows all institutional transactions in real time.
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
Live Leadership Updates
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H
QHP Capital, L.P. ("QHP"), an investor in technology and services companies in the life sciences and healthcare sectors, today announced its sale of Pro-ficiency, LLC ("Pro-ficiency" or the "Company"), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy. Michael Raymer, Chief Executive Officer of Pro-ficiency, said, "We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations wi
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today the appointment of Will Frederick as chief financial officer (CFO), succeeding John Kneisel, who retires after seven years with the company. Will Frederick brings more than 25 years of financial leadership experience to the company. He has a proven track record of developing and implementing strategies to drive revenue growth, increase profitability, managing merger & acquisition activities and achieving corporate objectives. He has global experience with both publicly traded and privately held companies including Pharsight, Entelos, Avaya, The Walt Disney Company and Ford Motor Company, among
Live finance-specific insights
Reaffirms fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10 Investor Day on January 21, 2026, to present new product vision and AI solutions Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025. Fourth Quarter 2025 Financial Highlights (as compared to fourth quarter 2024) Total revenue decreased 6% to $17.5 million Software revenue decreased 9% to $9.0 million, representi
Provides preliminary fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10 Fourth quarter and fiscal year 2025 results to be reported December 1, 2025 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary results for its fiscal year 2025 and issued preliminary guidance and management outlook for fiscal year 2026 as follows: Fiscal 2025 Preliminary Fiscal 2026 Guidance Revenue $
Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its third quarter fiscal 2025, ended May 31, 2025. Third Quarter 2025 Financial Highlights (as compared to third quarter 2024) Total revenue increased 10% to $20.4 million Software revenue increased 6% to $12.6 million, representing 62% of total revenue Services revenue increased 17% to $7.7 millio
Updates fiscal 2025 revenue guidance range Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue guidance. The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million Full year fiscal 2025 revenue is expected to range between $76 millio
Total revenue grew 23% year-over-year driven by strong growth in both software and services Maintains full-year revenue guidance of $90 to $93 million and adjusted diluted EPS of $1.07 to $1.20 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025. Second Quarter 2025 Financial Highlights (as compared to second quarter 2024) Total revenue increased 23% to $22.4 million Software revenue increased 16% to $13.5 million, repres
Conference call to be on Thursday, April 3, 2025, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accesse
Total revenue up 31% year-over-year primarily driven by strong software growth Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial Highlights (compared to first quarter 2024) Total revenue increased 31% to $18.9 million Software revenue increased 41% to $10.7 million, representing 57% of total revenue Services revenue increased 19% to $8.2 million, representing 43% of total revenue Gro
Conference call to be on Tuesday, January 7, 2025, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-4
Fiscal 2024 revenue grew 18% year-over-year to $70 million, with diluted earnings per share (EPS) of $0.49 Provides fiscal 2025 revenue guidance of $90 to $93 million (+28% to +33%) and adjusted diluted EPS guidance of $1.07 to $1.20 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its fourth quarter and fiscal 2024, ended August 31, 2024. Fourth Quarter 2024 Financial Highlights (compared to fourth quarter 2023) Total revenue increased 19% to $18.7 million Software revenue increased 6% to $
Conference call to be on Wednesday, October 23, 2024, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report fourth quarter and fiscal 2024 financial results after the market close on Wednesday, October 23, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be access